Comments
Loading...

ProQR Therapeutics

PRQRNASDAQ
Logo brought to you by Benzinga Data
$2.63
0.041.54%
At close: -
$2.71
0.083.10%
After Hours: Dec 19, 7:32 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$14.00
Lowest Price Target1
$2.00
Consensus Price Target1
$7.08

ProQR Therapeutics (NASDAQ:PRQR) Stock, Analyst Ratings, Price Targets, Forecasts

ProQR Therapeutics NV has a consensus price target of $7.08 based on the ratings of 6 analysts. The high is $14 issued by Raymond James on October 29, 2024. The low is $2 issued by Citigroup on April 18, 2024. The 3 most-recent analyst ratings were released by JMP Securities, Chardan Capital, and HC Wainwright & Co. on December 12, 2024, respectively. With an average price target of $7.33 between JMP Securities, Chardan Capital, and HC Wainwright & Co., there's an implied 170.45% upside for ProQR Therapeutics NV from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Oct
1
Nov
2
Dec
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

JMP Securities
Chardan Capital
HC Wainwright & Co.
Raymond James
Citigroup

1calculated from analyst ratings

Analyst Ratings for ProQR Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for ProQR Therapeutics (PRQR) stock?

A

The latest price target for ProQR Therapeutics (NASDAQ:PRQR) was reported by JMP Securities on December 12, 2024. The analyst firm set a price target for $8.00 expecting PRQR to rise to within 12 months (a possible 204.18% upside). 10 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for ProQR Therapeutics (PRQR)?

A

The latest analyst rating for ProQR Therapeutics (NASDAQ:PRQR) was provided by JMP Securities, and ProQR Therapeutics reiterated their market outperform rating.

Q

When was the last upgrade for ProQR Therapeutics (PRQR)?

A

The last upgrade for ProQR Therapeutics NV happened on October 29, 2024 when Raymond James raised their price target to $14. Raymond James previously had an outperform for ProQR Therapeutics NV.

Q

When was the last downgrade for ProQR Therapeutics (PRQR)?

A

The last downgrade for ProQR Therapeutics NV happened on August 12, 2022 when Chardan Capital changed their price target from N/A to N/A for ProQR Therapeutics NV.

Q

When is the next analyst rating going to be posted or updated for ProQR Therapeutics (PRQR)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ProQR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ProQR Therapeutics was filed on December 12, 2024 so you should expect the next rating to be made available sometime around December 12, 2025.

Q

Is the Analyst Rating ProQR Therapeutics (PRQR) correct?

A

While ratings are subjective and will change, the latest ProQR Therapeutics (PRQR) rating was a reiterated with a price target of $8.00 to $8.00. The current price ProQR Therapeutics (PRQR) is trading at is $2.63, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.